Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: A phase I clinical trial

• Published in: Cancer science 2019-12, Vol.110 (12), p.3650-3662
• Main Authors: Akazawa, Yu, Hosono, Ako, Yoshikawa, Toshiaki, Kaneda, Hide, Nitani, Chika, Hara, Junichi, Kinoshita, Yoshiaki, Kohashi, Kenichi, Manabe, Atsushi, Fukutani, Miki, Wakabayashi, Masashi, Sato, Akihiro, Shoda, Kayoko, Shimomura, Manami, Mizuno, Shoichi, Nakamoto, Yasunari, Nakatsura, Tetsuya
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Antigens; Bone cancer; Cancer therapies; Cancer Vaccines - immunology; Chemotherapy; Child; Clinical trials; Cloning; cytotoxic T lymphocyte; Cytotoxicity; Drug dosages; Ethics; Female; Forkhead Box Protein M1 - immunology; Glycoproteins; Guardians; Histocompatibility Antigens Class I - analysis; Hospitals; Humans; Immune response; Immunization; Immunology; Immunotherapy; Interferon; Kinases; Kinesin - immunology; Laboratories; Lymphocytes T; Male; Medical prognosis; Metastasis; NCCV Cocktail‐1; Neoplasms - immunology; Neoplasms - mortality; Neoplasms - therapy; Nervous system; Original; Patients; pediatric refractory solid tumor; Pediatrics; peptide vaccine; Peptides; phase I; Progression-Free Survival; Radiation therapy; Remission; RNA-Binding Proteins - immunology; Solid tumors; Survival; T-Lymphocytes, Cytotoxic - immunology; Tumors; Vaccination; Vaccines; Young Adult
• ISSN: 1347-9032; 1349-7006
• DOI: 10.1111/cas.14206

Pediatric refractory solid tumors are aggressive malignant diseases, resulting in an extremely poor prognosis. KOC1, FOXM1, and KIF20A are cancer antigens that could be ideal targets for anticancer immunotherapy against pediatric refractory solid tumors with positive expression for these antigens. This nonrandomized, open‐label, phase I clinical trial evaluated the safety and efficacy of the NCCV Cocktail‐1 vaccine, which is a cocktail of cancer peptides derived from KOC1, FOXM1, and KIF20A, in patients with pediatric refractory solid tumors. Twelve patients with refractory pediatric solid tumors underwent NCCV Cocktail‐1 vaccination weekly by intradermal injections. The primary endpoint was the safety of the NCCV Cocktail‐1 vaccination, and the secondary endpoints were the immune response, as measured by interferon‐r enzyme‐linked immunospot assay, and the clinical outcomes including tumor response and progression‐free survival. The NCCV Cocktail‐1 vaccine was well tolerated. The clinical response of this trial showed that 4 patients had stable disease after 8 weeks and 2 patients maintained remission for >11 months. In 4, 8, and 5 patients, the NCCV Cocktail‐1 vaccine induced the sufficient number of peptide‐specific CTLs for KOC1, FOXM1, and KIF20A, respectively. Patients with high peptide‐specific CTL frequencies for KOC1, FOXM1, and KIF20A had better progression‐free survival than those with low frequencies. The findings of this clinical trial showed that the NCCV Cocktail‐1 vaccine could be a novel therapeutic strategy, with adequate effects against pediatric refractory solid tumors. Future large‐scale trials should evaluate the efficacy of the NCCV Cocktail‐1 vaccination. Kaplan‐Meier curves for progression‐free survival. We found that patients with higher numbers of cancer antigens (KOC1, FOXM1, and KIF20A) that induced peptide‐specific CTLs by vaccination had better progression‐free survival.